-
Boston College Law School, J.D., cum laude
-
University of Delaware
Part-time graduate studies in Chemistry while employed at DuPont Pharmaceutical Company
-
Johns Hopkins University, B.A., Chemistry
- Massachusetts
- U.S. Patent & Trademark Office
- U.S. Court of Appeals, First Circuit
- U.S. Court of Appeals, Federal Circuit
-
American Bar Association
- Boston Patent Law Association
- Licensing Executives Society
- American Intellectual Property Law Association
- American Chemical Society
- Association of University Technology Managers
|
 | |
Peter
F.
Corless
Edwards Wildman Palmer LLP
Partner
Boston
Tel 617.517.5557
Fax 888-325-9132
 Download VCard
|
Peter is Co-Chair of the firm's Patent Practice Group. Peter's practice is devoted to patent prosecution and patent licensing and litigation in the technology areas of pharmaceuticals, specialty chemicals, biotechnology, medical devices and other mechanical and electro-mechanical innovations particularly as relating to the automotive industry.
Peter's clients include academic and governmental research institutions; Global 1000 manufacturing, chemical and pharmaceutical companies; emerging and developing biotechnology and small molecule pharmaceutical companies; and medical device companies.
Peter prosecutes and manages extensive patent and trademark portfolios on behalf of companies and academic institutions located throughout the United States, Asia, and Europe. Peter has been included in the New England Super Lawyers listing, a Thomson Reuters publication, each year since 2004. He is rated AV Preeminent by Martindale-Hubbell. Peter has been quoted on intellectual property topics in various publications, including The New York Times, Bloomberg, The Los Angeles Times, The Boston Globe, American Lawyer and Boston Business Journal.
Notable Experience
- Peter has considerable experience in patent prosecution matters. Peter has prepared, prosecuted and managed extensive patent portfolios for global manufacturing companies. Peter also has drafted and prosecuted patent applications covering pharmaceutical, biotechnology and medical device products that are currently in Phase II and III trials as well as in approved clinical use in the United States and abroad. Peter has obtained patents that have yielded tens of millions of dollars in royalties as well as provided the basis for private and public financings of companies located throughout the United States, Asia, and Europe.
- Peter also represents parties in intellectual property disputes, including patent and trademark infringement actions. Peter has represented both opponents and patentees in numerous oppositions in Europe, Japan and Australia. Peter regularly provides opinions on issues of patent infringement and validity.
- Peter has served as the President of the Boston Patent Law Association (BPLA). Peter has also served as Co-Chair of the BPLA's Amicus Committee, Chair of the Chemical Patent Practice Committee and on the Board of Governors of the BPLA.
Peter is Co-Chair of the Firm's Patent Practice Group. Peter's practice is devoted to patent prosecution and patent licensing and litigation in the technology areas of pharmaceuticals, specialty chemicals, biotechnology, medical devices and other mechanical and electro-mechanical innovations particularly as relating to the automotive industry. Peter's clients include academic and governmental research institutions; Global 1000 manufacturing, chemical and pharmaceutical companies; emerging and developing biotechnology and small molecule pharmaceutical companies; and medical device companies. Peter prosecutes and manages extensive patent and trademark portfolios on behalf of companies and academic institutions located throughout the United States, Asia, and Europe. Peter has been included in the New England Super Lawyers listing, a Thomson Reuters publication, each year since 2004. He is rated AV Preeminent by Martindale-Hubbell. Notable Experience - Peter has considerable experience in patent prosecution matters. Peter has prepared, prosecuted and managed extensive patent portfolios for global manufacturing companies. Peter also has drafted and prosecuted patent applications covering pharmaceutical, biotechnology and medical device products that are currently in Phase II and III trials as well as in approved clinical use in the United States and abroad. Peter has obtained patents that have yielded tens of millions of dollars in royalties as well as provided the basis for private and public financings of companies located throughout the United States, Asia, and Europe.
- Peter also represents parties in intellectual property disputes, including patent and trademark infringement actions. Peter has represented both opponents and patentees in numerous oppositions in Europe, Japan and Australia. Peter regularly provides opinions on issues of patent infringement and validity.
Recent Speaking Engagements and Publications
- "A License to Life: Monsanto’s Seed Patents," co-author, Intellectual Property Magazine, April 2013.
- "Should Your Start-ups be Carrying Infringement Insurance," quoted, Technology Transfer Tactics, February 2013.
- “USPTO Publishes Final Rules and Examination Guidelines for Implementing First-Inventor-to-File Provisions of America Invents Act,” co-author, Edwards Wildman Palmer LLP Client Advisory, February, 2013.
- "Monsanto’s Supreme Court Case Affects Industries Beyond Seed," quoted, Bloomberg Law, February 13, 2013.
- “Direct Infringement by Single Entity Not Necessary for Induced Infringement of Method Patent,” co-author, Edwards Wildman Palmer LLP Client Advisory, September 2012.
- “Biomedical Diagnostic Patents Post-Prometheus,” co-author, Edwards Wildman Palmer LLP Client Advisory, March 2012.
- “US-Korea Free Trade Agreement and Patent Rights,” co-author, Bloomberg Law Reports, October 31, 2011.
- “Recent Patent Law Developments that Affect Protection of Drug Discoveries,” speaker, 3rd Annual Drug Discovery Partnership: Filling the Pipeline, Boston, Massachusetts, October 17, 2011.
- Fu Jen International Academic Symposium on Patent Litigation and U.C. Competition Law & International Mock Trial, presenter, New Taipei City, Taiwan, April 11-12, 2011.
- “Key Patent Considerations for Software and Life Science Innovations,” speaker, Your Competitive Advantage: The Basics of Intellectual Property Protection seminar presented by The USF Chapter of the National Academy of Inventors, April 22, 2011.
- "In Whose Best Interest? Finding Common Ground to Patenting," panelist, 2nd Annual Drug Discovery Partnership: Filling the Pipeline, October 28 - 29, 2010.
- "Maximizing the Value of Your IP Portfolio and Safeguarding Product IP Ownership," presenter, Medical Devices Summit 2010, March 1 - 3, 2010.
- "Maximizing the Value of Your IP Portfolio," speaker, Drug Discovery Partnership: Filling the Pipeline, October 28 – 30, 2009.
- Peter was an invited speaker on patent law at the BioFlorida Annual Meeting, November 2006.
- Peter was an invited speaker at the Advanced Forum on Biotech Patents in Boston, Massachusetts.
- Peter was an invited speaker on patent protection for pharmaceutical inventions at the American Chemical Society Annual Meeting.
- Peter was an invited speaker on patent law at the American Heart Association Scientific Sessions Annual Meeting in Anaheim, California.
- Peter has lectured on intellectual property law topics for the Patent Resources Group (PRG) and the Boston Patent Law Association.
- Peter has authored technical papers in publications such as Journal of Medicinal Chemistry and Synthesis.
- Peter is an author of "Taking the USPTO Route To Challenging a Patent," Patent World, May 2005, "Recombinant DNA Inventions After Fiers," Houston Journal of International Law.
Before Edwards Wildman
Prior to attending law school, Peter was a synthetic organic chemist in a drug discovery group of E.I. DuPont de Nemours Co., Medical Products Department (later the DuPont Pharmaceutical Company and now merged with Bristol-Myers Squibb), in Wilmington, Delaware. Peter is an inventor on U.S. Patent 4,977,173 "Aminomethyl Oxooxazolidinyl Ethenylbenzene Derivatives Useful As Antibacterial Agents," which covers predecessor development compounds to Pfizer's oxazolidinone antibacterial Zyvox, now in clinical use.
Besides Edwards Wildman
Peter is active in a variety of youth sports programs, including coaching local soccer, wrestling, and baseball teams, and has served as the Director of the Wellesley Youth Wrestling Program. Peter also regularly golfs and skis with his sons and daughter.
|
|